PDCD1 and non-small cell lung carcinoma: Overall, our study suggests that PD-1 inhibitors are associated with a higher incidence of irAEs in patients with NSCLC, particularly in those with stage IV disease, and that smoking, TNM staging, NLR, SII, and PNI are significant predictors of irAEs.